Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2002
10/08/2002US6462069 Kinase inhibitors; anticancer agents
10/08/2002US6462068 Heterocyclylmethyl-substituted pyrazole derivatives
10/08/2002US6462067 Administering histamine or salt derivative; preventing and/or reducing oxidative cellular and tissue damage; inflammatory diseases, including rheumatoid arthritis, crohn's disease, and adult respiratory distress syndrome
10/08/2002US6462066 Method and composition for treatment of ischemic neuronal reperfusion injury
10/08/2002US6462065 Use of 5-HT3 receptor antagonists for treating musculoeskeletal diseases
10/08/2002US6462064 Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias
10/08/2002US6462062 Compounds and methods for use thereof in the treatment of cancer or viral infections
10/08/2002US6462061 Omega chain modified 15-hydroxyeicosatetraenoic acid derivatives and methods of their use for treatment of dry eye
10/08/2002US6462060 Heterocyclic-hydroxyimino-fluorene nuclei compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
10/08/2002US6462058 Benzimidazole compound crystal
10/08/2002US6462057 Compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
10/08/2002US6462056 Oxazolidines as 5-HT2A-antagonists
10/08/2002US6462055 Alpha-methylbenzyl-containing thiourea inhibitors of herpes viruses containing a phenylenediamine group
10/08/2002US6462054 Alpha keto heterocyclic pharmacophore; complementary binding by electrophilic carbonyl and weakly basic nitrogen of such as oxazolopyridine group; sleep aids or analgesics; preserving endogenous levels of oleamide and anandamide
10/08/2002US6462051 Composition for reducing mental fatigue, composition for maintaining and enhancing concentration, and composition for maintaining and enhancing mental vigor
10/08/2002US6462048 3-(2-(4-methylpiperazin-1-yl)-benzylidene)-1,3-dihydro-indol-2-one for example; useful as psychotherapeutic agents
10/08/2002US6462047 Containing 5- or 6-membered oxygen, nitrogen and/or sulfur heteroaryl group; angina, hypertension, respiratory distress, congestive heart failure, renal failure, atherosclerosis, inflammatory diseases, strokes, bronchitis, asthma
10/08/2002US6462045 Method of treating pulmonary hypertension
10/08/2002US6462044 Therapy for sexual disorders
10/08/2002US6462041 Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis
10/08/2002US6462040 Microbiocides; bacteriocides; antiprotozoa agents; quinolone antibiotics; side effect reduction; antibiotic-resistant bacteria including staphyloccocus; veterinary medicine
10/08/2002US6462038 Such as 1,2,3,6-tetrahydro-1-methyl-9-(trifluoromethyl)-7h-(1,4)oxazino(3,2 -g)quinolin-7-one; nonsteroidal, high affinity and specificity antagonists and agonists or partial agonists, i.e. partial and/or tissue specific activators
10/08/2002US6462036 Inhibiting signal transduction by modulating activity of receptor and nonreceptor tyrosine and serine/threonine kinases to regulate and modulate abnormal or inappropriate cell proliferation, differentiation, or metabolism
10/08/2002US6462035 Binding to neuronal nicotinic acetylcholine specific receptor; modulating cholinergic function; reducing nicotine addiction; inflammatory and irritable bowel syndrome, spastic dystonia, chronic and acute pain, eating disorders
10/08/2002US6462033 Topical mixture
10/08/2002US6462032 Cyclic regimens utilizing indoline derivatives
10/08/2002US6462030 Method for inactivating bacteria associated with bacterial vaginosis using cellulose acetate phthalate and/or hydroxypropyl methycellulose phthalate
10/08/2002US6462029 Diseases and/or conditions caused by circulating agents such as poisonous heavy metals, environmental toxins, calcium and cholesterol
10/08/2002US6462028 P2y2 and/or p2y4 purinergic receptor agonists e.g., nucleotides of adenosine, cytidine and uridine, dinucleotides and analogs; treating vaginal dryness associated with menopause, chemotherapy, and diseases; vulvar pain
10/08/2002US6462025 Shel flife and convenient dispensing; for therapy of acne
10/08/2002US6462024 Use of inhibitors of the sodium-hydrogen exchanger for the production of a medicament for decreasing undesired effects of substrates of the heart
10/08/2002US6462023 Cytostatic agents
10/08/2002US6462021 Melagatran or derivative; nonvalvular atrial fibrillation; thrombotic or ischemic stroke, transient ischemic attack or systemic embolism
10/08/2002US6462019 Inhibitors of proteasomal activity and production for stimulating bone growth
10/08/2002US6462017 Method of reducing side effects of chemotherapy in cancer patients
10/08/2002US6461851 High expression modules containing two or more tandem copies of a methioninase encoding sequence
10/08/2002US6461848 Degrades heparin sulfate preventing deposits of beta-amyloid senile plaques
10/08/2002US6461822 Therapeutic targets for agents that suppress the release of inflammatory mediators such as interleukin il-1 and il-1 beta
10/08/2002US6461806 Measuring isotope labelled dna synthesis and destruction; cancer diagnosis; prognosing human immunodeficiency virus
10/08/2002US6461648 Solvent extraction of berries
10/08/2002US6461643 Consists of at least one biologically- active agent; (b) at least one carrier comprising an acylated aldehyde of an amino acid, an acylated ketone of an amino acid, an acylated aldehyde of a peptide, an acylated ketone of a peptide
10/08/2002US6461642 Crystallization using supercritical or subcritical fluids
10/08/2002US6461641 Adding to bioactive agent polymeric vehicle which gels or solidifies at time of or shortly after injection and has consistency and density to displace cells and to retain bioactive agent at injection site, thereby enhancing delivery
10/08/2002US6461639 First layer comprising troglitazone as active ingredient, core enclosed by first layer comprising a biguanide as active ingredient, polysaccharide polymer; sustained drug release; antidiabetic agents
10/08/2002US6461637 Method of administering liposomal encapsulated taxane
10/08/2002US6461636 Matrix mass containing (meth)acrylate copolymer having ammonio groups or mixture of (meth)acrylate copolymer having amino groups with one having carboxyl groups, propylene glycol and pergolide surrounded by larger plaster for fixing to skin
10/08/2002US6461635 Method of forming a barrier on an epidermal surface
10/08/2002US6461625 Nanoemulsion based on alkoxylated alkenyl succinates or alkoxylated alkenyl succinates of glucose and its uses in the cosmetics, dermatological, opthalmological and/or pharmaceutical fields
10/08/2002US6461619 Method for treating wounds, burns and dermatological damage by administering selegiline or desmethylselegiline
10/08/2002US6461607 Probiotic, lactic acid-producing bacteria and uses thereof
10/08/2002US6461605 Continuous low-dose cytokine infusion therapy
10/08/2002US6461602 Water-soluble, nontoxic prodrugs having a hydrolyzable carbamate group coupling the drug or active ingredient to a modified polymer; insoluble drug released in vivo; drug delivery
10/08/2002US6461601 Polyalkoxy copolymers as lipase inhibitors and their compositions
10/08/2002US6461600 Analgesic in cream carrier
10/08/2002US6461593 Therapy with coenzyme Q10 to reduce subgingival microorganisms in patients with periodontal disease
10/08/2002US6461591 Storage stability
10/08/2002US6461588 Use of bile acid conjugates, derivatives thereof with metal complexes as blood pool agents for nuclear magnetic resonance diagnostics
10/08/2002US6461545 Method of solubilizing and encapsulating itraconazole
10/08/2002CA2252982C Substituted indazole derivatives and their use as inhibitors phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
10/08/2002CA2250243C Thiazoline acid derivatives
10/08/2002CA2220995C New derivatives of substituted 7,12-dioxa-benzo¬a|anthracenes, their preparation process and the pharmaceutical compositions they contain
10/08/2002CA2196769C Benzimidazole derivatives having dopaminergic activity
10/08/2002CA2172354C Benzazepine-, benzoxazepine- and benzothiazepine-n-acetic acid derivatives, process for their preparation and pharmaceutical compositions containing them
10/08/2002CA2145775C 1,4-disubstituted piperazines useful in the therapy of the asthma and of the inflammation of the respiratory tract
10/08/2002CA2108967C Arylmorpholine, preparation and use
10/08/2002CA2095361C Optical isomers of 7-¬3-(1,1-dialkylmethyl-1-amino)-1-pyrrolidinyl|-quinolones and naphthyridones as antibacterial agents
10/08/2002CA2089369C Antibacterial penem compounds
10/08/2002CA2084489C Crystalline fumaric acid salts of 9,9-alkylene-3, 7-diazabicyclononane compounds and pharmaceutical compositions containing them
10/08/2002CA2081766C Leukotriene b4 antagonists
10/08/2002CA2066083C Benzodiazepine analogs as cholecystokinin antagonists
10/08/2002CA2037092C Bile acid unsaturated derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
10/07/2002WO2001076598A1 Stabilized pharmaceutical compositions containing calcium channel blockers
10/06/2002WO2003088897A2 Fab i inhibitors
10/06/2002CA2444597A1 Fab i inhibitors
10/05/2002CA2380381A1 Combination treatment of multiple sclerosis (ms) other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
10/03/2002WO2002077609A2 Identification of compounds for the treatment or prevention of proliferative diseases
10/03/2002WO2002077290A1 Methods for modifying pharmacokinetics and bioavailability of exogenous compounds
10/03/2002WO2002077267A2 Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
10/03/2002WO2002077266A2 Novel fibroblast growth factor and nucleic acids encoding same
10/03/2002WO2002077263A2 Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
10/03/2002WO2002077255A1 Topoisomerase i selective cytotoxic sugar derivatives of indolopyrrolocarbazoles
10/03/2002WO2002077251A1 Method of recovering pinitol or chiro-inositol in high yield from soy fractions
10/03/2002WO2002077217A2 Human dual specificity protein phosphatase 7-like protein
10/03/2002WO2002077184A2 Oligonucleotide conjugates
10/03/2002WO2002077092A1 Highly nucleated thermoplastic articles
10/03/2002WO2002077074A1 Compounds for a controlled release of active compounds
10/03/2002WO2002077027A1 Human stra6-like protein and nucleic acids encoding the same
10/03/2002WO2002077023A2 A new essential downstream component of the wingless signalling pathway
10/03/2002WO2002077017A2 Medical uses of intercellular communication facilitating compounds
10/03/2002WO2002077008A1 A composition containing novel compound corniculatonin having antifungi properties and a process for preparing the same
10/03/2002WO2002077007A2 Novel polyaminated fusidic acid derivatives
10/03/2002WO2002077005A1 Pesticidal spinosyn derivatives
10/03/2002WO2002077004A1 Synthetic derivatives of 21-butenyl and related spinosyns
10/03/2002WO2002077003A1 Process for obtaining lignan, pharmaceutical compositions and uses thereof
10/03/2002WO2002076995A2 2-amino-propanol derivatives
10/03/2002WO2002076993A1 Tumor-inhibiting silicon compounds
10/03/2002WO2002076990A1 Thiazolopyrimidine derivatives and use thereof as antagonists of the cx3 cr1 receptor
10/03/2002WO2002076989A1 Protein phosphate inhibitors
10/03/2002WO2002076987A1 (oxo-pyrazolo[1,5a]pyrimidin-2-yl)alkyl-carboxamides
10/03/2002WO2002076986A1 Pyrazolopyrimidines as therapeutic agents
1 ... 5688 5689 5690 5691 5692 5693 5694 5695 5696 5697 5698 5699 5700 5701 5702 5703 5704 5705 5706 5707 5708 ... 7860